Clinical Trials
20 trialsNCT05341947 2025-10-22
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Withdrawn
NCT06501911 2025-07-22
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
Phase 1 Withdrawn
NCT05773664 2024-09-19
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT04741984 2023-05-15
DEMAND
Duke University
Phase 1 Withdrawn
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT04854044 2021-05-12
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04270461 2020-10-22
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
Phase 1 Withdrawn
NCT03480867 2019-08-14
PARADIGMA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 1 Withdrawn
NCT03275558 2018-07-19
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
Phase 1 Withdrawn
NCT00703859 2016-02-22
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
AHS Cancer Control Alberta
Phase 1 Withdrawn
NCT01861990 2015-05-22
Valproic Acid in Childhood Progressive Brain Tumors
Medical University of South Carolina
Phase 1 Withdrawn
NCT01317212 2015-04-17
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
North Bristol NHS Trust
Phase 1 Withdrawn
NCT02055196 2014-06-02
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT01854099 2014-01-14
PERFORMANCE
University of Florida
Phase 1 Withdrawn
NCT00734864 2012-11-21
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
Duke University
Phase 1 Withdrawn
NCT01189513 2012-02-20
SCH-900105 in Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn